600645 Vcanbio Cell & Gene Engineering Corp.,Ltd.
- 18.75
- +0.57+3.14%
Vcanbio Cell & Gene Engineering Corp.,Ltd. News
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2024 First Extraordinary General Meeting of Shareholders Meeting Data
Notice of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on convening the first extraordinary shareholders\' meeting in 2024
Announcement of Zhongyuan Union Cell Genetic Engineering Co., Ltd. on the appointment of an accounting firm
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the wholly-owned subsidiary obtaining a notice of approval for drug clinical trials
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the replacement of the sponsor of the financial advisor for continuous supervision
The selection system for accounting firms of Vcanbio Cell & Gene Engineering Corp., Ltd.
Announcement of vcanbio cell & gene engineering corp.,ltd. obtaining acceptance notice for pharmaceutical clinical trial application by its wholly-owned subsidiary.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Legal Opinion of Beijing Guofeng Law Firm on the 2023 Annual General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
An indicative announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on holding the 2023 Annual General Meeting of Shareholders
Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. 2023 Annual General Meeting of Shareholders Meeting Data
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on accruing asset impairment losses
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the extension of the fund-raising project
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2023 Internal Control Evaluation Report
2023 Independent Director Debriefing Report of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. (Chen Min - Retirement after term)
Report on the performance of the Audit Committee of the Board of Directors of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. 2023
Report on the audit committee of the board of directors of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.'s performance of supervisory duties on the accounting firm
Notice of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on holding the 2023 Annual General Meeting of Shareholders
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the completion of group administration of its wholly-owned subsidiary VUM02 injection to treat the first case of idiopathic pulmonary fibrosis
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the shareholding status of the top ten shareholders and the top ten shareholders with unlimited sales conditions in the share repurchase matter
Analysis
Price Target
No Data
No Data